University of Milan, Division of Rheumatology, Istituto G. Pini, Department of Clinical Sciences and Community Health , P.za Cardinal Ferrari 1, 20122 Milan , Italy +3958296272 ; +3958296315 ;
Expert Opin Pharmacother. 2013 Oct;14(14):1875-84. doi: 10.1517/14656566.2013.816286. Epub 2013 Jul 25.
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for reducing pain and other symptoms in osteoarthritis (OA). NSAIDs have been associated with an increase in blood pressure (BP) in both normotensive and hypertensive individuals and a blunting effect on various anti-hypertensive medications. Acetaminophen effects on anti-hypertensive treatment, instead, are still a matter of debate.
To assess the effect of naproxen versus acetaminophen on ramipril, valsartan and aliskiren therapy in hypertensive patients with OA in a double-blind, cross-over study, by measuring clinic, ambulatory BP and heart rate (HR).
One hundred seventy four patients were randomly treated with ramipril, valsartan or aliskiren for 8 weeks and 135 patients with normalized BP were randomized to receive naproxen or acetaminophen for 2 weeks. Naproxen significantly increased clinic and ambulatory systolic/diastolic BP (SBP/DBP) values in patients treated with ramipril (p < 0.01) or valsartan (p < 0.05), but did not affect aliskiren effects. Also acetaminophen slightly but significantly affected clinic and ambulatory SBP/DBP in all three groups and, surprisingly, it also produced a slight increase in HR (+3.1, +3.3 and +3.4 b/min day-time HR values, for ramipril, valsartan and aliskiren, respectively; p < 0.05).
Both naproxen and acetaminophen can affect anti-hypertensive therapy with ramipril, valsartan or aliskiren with a different extent. When acetaminophen is chosen for OA management in subjects with hypertension, patients should be evaluated as carefully as when traditional NSAIDs are given.
非甾体抗炎药(NSAIDs)常用于减轻骨关节炎(OA)患者的疼痛和其他症状。NSAIDs 已被证明会增加正常血压和高血压个体的血压(BP),并减弱各种抗高血压药物的作用。而对乙酰氨基酚对降压治疗的影响仍存在争议。
通过测量诊室、动态血压和心率(HR),在一项双盲、交叉研究中评估萘普生与对乙酰氨基酚对 OA 合并高血压患者接受雷米普利、缬沙坦和阿利克仑治疗的影响。
174 名患者随机接受雷米普利、缬沙坦或阿利克仑治疗 8 周,135 名血压正常的患者随机接受萘普生或对乙酰氨基酚治疗 2 周。萘普生显著增加了接受雷米普利(p < 0.01)或缬沙坦(p < 0.05)治疗的患者的诊室和动态收缩压/舒张压(SBP/DBP)值,但对阿利克仑的影响无影响。此外,对乙酰氨基酚也轻微但显著地影响了所有三组患者的诊室和动态 SBP/DBP,而且令人惊讶的是,它还使 HR 略有升高(日间 HR 值分别增加 3.1、3.3 和 3.4 次/分钟,雷米普利、缬沙坦和阿利克仑组;p < 0.05)。
萘普生和对乙酰氨基酚均可不同程度地影响雷米普利、缬沙坦或阿利克仑的降压治疗。当在高血压患者中选择对乙酰氨基酚治疗 OA 时,应像给予传统 NSAIDs 时一样仔细评估患者。